跳至主要内容
临床试验/NL-OMON54838
NL-OMON54838招募中不适用

The Diagnostic and Predictive Value of Different Biomarkers in Pancreatic Juice and Blood in Patients with Pancreatic Cancer. - KRAS mutation as a diagnostic biomarker.

Erasmus MC, Universitair Medisch Centrum Rotterdam0 个研究点目标入组 530 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
530

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • Patients with (suspected) pancreatic tumour, chronic pancreatitis and healthy
  • controls (non-pancreatic non-healthy) that undergo an endoscopic ultrasound or
  • The latter group is defined as all individuals undergoing endoscopic ultrasound
  • or ERCP for a non-pancreatic indication (e.g. choledocholithiasis), individuals
  • with a personal history with pancreatic disease (including pancreatic cysts,
  • pancreatitis or any other pancreas-related disease, post-surgery) or autoimmune
  • disease will not be included in this group. In addition, patients with a
  • history of malignancy could only be included if they have been treated
  • curatively >5 years ago.

排除标准

  • Age < 18 years.

研究者

相似试验